Inhibitors of the salicylate synthase (Mbti) from Mycobacterium tuberculosis discovered by high-throughput screening

Mahalakshmi Vasan, João Neres, Jessica Williams, Daniel J. Wilson, Aaron M. Teitelbaum, Rory P. Remmel, Courtney C. Aldrich

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A simple steady-state kinetic high-throughput assay was developed for the salicylate synthase MbtI from Mycobacterium tuberculosis, which catalyzes the first committed step of mycobactin biosynthesis. The mycobactins are small-molecule iron chelators produced by M. tuberculosis, and their biosynthesis has been identified as a promising target for the development of new antitubercular agents. The assay was miniaturized to a 384-well plate format and high-throughput screening was performed at the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB). Three classes of compounds were identified comprising the benzisothiazolones (class I), diarylsulfones (class II), and benzimidazole-2-thiones (class III). Each of these compound series was further pursued to investigate their biochemical mechanism and structure-activity relationships. Benzimidazole-2-thione 4 emerged as the most promising inhibitor owing to its potent reversible inhibition.

Original languageEnglish (US)
Pages (from-to)2079-2087
Number of pages9
JournalChemMedChem
Volume5
Issue number12
DOIs
StatePublished - Dec 3 2010

Fingerprint

Thiones
Salicylates
Biosynthesis
Mycobacterium tuberculosis
Assays
Screening
Throughput
Emerging Communicable Diseases
Antitubercular Agents
Structure-Activity Relationship
Chelating Agents
Iron
Molecules
Kinetics
benzimidazole
mycobactins
1,2-benzisothiazoline-3-one

Keywords

  • High-throughput screening
  • Mycobactins
  • Salicylate synthase
  • Siderophores
  • Tuberculosis

Cite this

Inhibitors of the salicylate synthase (Mbti) from Mycobacterium tuberculosis discovered by high-throughput screening. / Vasan, Mahalakshmi; Neres, João; Williams, Jessica; Wilson, Daniel J.; Teitelbaum, Aaron M.; Remmel, Rory P.; Aldrich, Courtney C.

In: ChemMedChem, Vol. 5, No. 12, 03.12.2010, p. 2079-2087.

Research output: Contribution to journalArticle

@article{692b6f9ac8484f7db33c9f5f8d2890cc,
title = "Inhibitors of the salicylate synthase (Mbti) from Mycobacterium tuberculosis discovered by high-throughput screening",
abstract = "A simple steady-state kinetic high-throughput assay was developed for the salicylate synthase MbtI from Mycobacterium tuberculosis, which catalyzes the first committed step of mycobactin biosynthesis. The mycobactins are small-molecule iron chelators produced by M. tuberculosis, and their biosynthesis has been identified as a promising target for the development of new antitubercular agents. The assay was miniaturized to a 384-well plate format and high-throughput screening was performed at the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB). Three classes of compounds were identified comprising the benzisothiazolones (class I), diarylsulfones (class II), and benzimidazole-2-thiones (class III). Each of these compound series was further pursued to investigate their biochemical mechanism and structure-activity relationships. Benzimidazole-2-thione 4 emerged as the most promising inhibitor owing to its potent reversible inhibition.",
keywords = "High-throughput screening, Mycobactins, Salicylate synthase, Siderophores, Tuberculosis",
author = "Mahalakshmi Vasan and Jo{\~a}o Neres and Jessica Williams and Wilson, {Daniel J.} and Teitelbaum, {Aaron M.} and Remmel, {Rory P.} and Aldrich, {Courtney C.}",
year = "2010",
month = "12",
day = "3",
doi = "10.1002/cmdc.201000275",
language = "English (US)",
volume = "5",
pages = "2079--2087",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Inhibitors of the salicylate synthase (Mbti) from Mycobacterium tuberculosis discovered by high-throughput screening

AU - Vasan, Mahalakshmi

AU - Neres, João

AU - Williams, Jessica

AU - Wilson, Daniel J.

AU - Teitelbaum, Aaron M.

AU - Remmel, Rory P.

AU - Aldrich, Courtney C.

PY - 2010/12/3

Y1 - 2010/12/3

N2 - A simple steady-state kinetic high-throughput assay was developed for the salicylate synthase MbtI from Mycobacterium tuberculosis, which catalyzes the first committed step of mycobactin biosynthesis. The mycobactins are small-molecule iron chelators produced by M. tuberculosis, and their biosynthesis has been identified as a promising target for the development of new antitubercular agents. The assay was miniaturized to a 384-well plate format and high-throughput screening was performed at the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB). Three classes of compounds were identified comprising the benzisothiazolones (class I), diarylsulfones (class II), and benzimidazole-2-thiones (class III). Each of these compound series was further pursued to investigate their biochemical mechanism and structure-activity relationships. Benzimidazole-2-thione 4 emerged as the most promising inhibitor owing to its potent reversible inhibition.

AB - A simple steady-state kinetic high-throughput assay was developed for the salicylate synthase MbtI from Mycobacterium tuberculosis, which catalyzes the first committed step of mycobactin biosynthesis. The mycobactins are small-molecule iron chelators produced by M. tuberculosis, and their biosynthesis has been identified as a promising target for the development of new antitubercular agents. The assay was miniaturized to a 384-well plate format and high-throughput screening was performed at the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB). Three classes of compounds were identified comprising the benzisothiazolones (class I), diarylsulfones (class II), and benzimidazole-2-thiones (class III). Each of these compound series was further pursued to investigate their biochemical mechanism and structure-activity relationships. Benzimidazole-2-thione 4 emerged as the most promising inhibitor owing to its potent reversible inhibition.

KW - High-throughput screening

KW - Mycobactins

KW - Salicylate synthase

KW - Siderophores

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=78651495098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651495098&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201000275

DO - 10.1002/cmdc.201000275

M3 - Article

C2 - 21053346

AN - SCOPUS:78651495098

VL - 5

SP - 2079

EP - 2087

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 12

ER -